CD64, also known as Fc gamma receptor I (FcγRI), is a high-affinity receptor for the Fc region of immunoglobulin G (IgG). It plays a crucial role in the immune system by mediating various immune responses, including phagocytosis, antibody-dependent cellular cytotoxicity (ADCC), and the release of inflammatory mediators. CD64 is primarily expressed on monocytes, macrophages, dendritic cells, and activated granulocytes .
CD64 is a 72 kDa type I transmembrane glycoprotein. It associates with a signaling FcRγ homodimer to form the functional high-affinity FcγRI complex . This receptor is unique among Fcγ receptors due to its high affinity for monomeric IgG, particularly the IgG1 and IgG3 subclasses . This high affinity allows CD64 to bind IgG even at low concentrations, making it a critical player in immune responses.
CD64 is involved in various immune functions:
CD64 has emerged as an attractive target for immunotherapy, particularly in the treatment of chronic inflammatory diseases. Dysregulated macrophages expressing CD64 play a key role in the initiation and maintenance of these diseases . Targeting CD64 with specific antibodies or immunotherapeutic agents can selectively eliminate these disease-causing macrophages, offering a promising strategy for treating conditions such as rheumatoid arthritis, atopic dermatitis, and autoimmune disorders .
Mouse anti-human CD64 antibodies are widely used in research and clinical applications. These antibodies can be used in various techniques, including flow cytometry, immunohistochemistry, Western blotting, immunocytochemistry, and ELISA . They are valuable tools for studying CD64 expression, function, and its role in disease processes.